Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Merck cut its 2025 adjusted earnings projection to a range between $8.82 and $8.97 a share from a previous estimate of $8.88 to $9.03 a share. The new guidance includes a charge of roughly $200 ...

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

Two new cases of polio have been confirmed in Hadejia and Suletankarkar Local Government Areas of Jigawa State, marking a ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between the US and China, where demand for its blockbuster Gardasil vaccine is ...

The drugmaker is still dealing with the fallout over its HPV vaccine Gardasil in China, where a drop in demand forced it to halt shipments and rescind its previous forecast of $11 billion in ...

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...

The company’s head of ad marketing says Roku is always tweaking and testing — but the ads push is only going to keep growing. The company’s head of ad marketing says Roku is always tweaking ...